DESTINY Breast Respond HER2-low Europe
Status: RECRUITING
Study type: OBSERVATIONAL
Conditions: Unresectable Breast Cancer|Metastatic Breast Cancer|HER2-low Expressing Breast Cancer
Interventions: DRUG: Trastuzumab deruxtecan
Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company